Infectious Disease Focus MDL is a CLIA-certified infectious disease laboratory specializing in high-complexity PCR-based molecular diagnostics with a broad portfolio across urology, obstetrics/gynecology, respiratory infections, vector-borne diseases, mycology, and pharmacogenomics, presenting multiple cross-sell opportunities to hospitals, clinics, and reference labs seeking comprehensive pathogen panels.

Single-Swab Testing The OneSwab, UroSwab, and NasoSwab platforms enable multiple pathogen detections from a single sample, offering a compelling value proposition for streamlined workflows, improved patient experience, and higher test multiplexing potential for integrated infection panels.

Expansion Potential MDL has recently launched urology-specific testing and has partnerships with health systems (e.g., East Point COVID-19 testing program), indicating openness to new clinical areas and regional collaborations that could be scaled with enterprise clients, academic centers, or public health programs.

R&D & Collaboration MDL's active R&D and contractual research work for major organizations suggest opportunities for joint development, custom assay validation, and research collaborations with biopharma, diagnostics developers, or government agencies seeking advanced molecular testing capabilities.

Strategic Fit & Growth With a revenue range of 50–100 million and a mid-size employee base, MDL presents a strategic partner for scalable lab services, contract testing, and managed services, particularly for healthcare networks seeking high-sensitivity PCR diagnostics and integrated pathogen testing across specialties.